海外の治験の状況「1」での検索結果
2039件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Feasibility study to test an insulin dosing algorithm in type 1 diabetic patients
- Diabetes mellitus type 1;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
- Austria
- 2013-01-10
Authorised
- Empagliflozin as Adjunctive to inSulin thErapy in Type 1 diabetes over 52 weeks (EASE-2)
- Type 1 diabetes mellitus br>MedDRA version: 19.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Netherlands, Norway, Poland, Spain, Sweden, Taiwan, United Kingdom, United States
- 2015-04-02
Authorised
- The comparison of the number of insulin-producing cells during and shortly after the honeymoon phase of type 1 diabetes
- Type 1 diabetes MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Netherlands
- 2017-11-13
Authorised
- A Study to Assess the Long-term Safety of Rechon Insulin Human Soluble in Type 1 Diabetic Patients.
- Type 1 Diabetes MedDRA version: 20.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Germany, Poland
- 2017-08-29
Authorised
- Fibrinogen (blood protein) supplementation in patients that have developed fibrinogen deficiency during surgery.
- The sequence of events culminating in Pseudomyxoma peritonei (PMP) is thought to involve growth of an appendiceal adenoma with distension of the appendix by mucus and mucinous tumour cells. The appendix eventually ruptures. Patients undergoing the PMP surgery develop a coagulopathy predominantly characterised by reduced levels of fibrinogen, resulting in reduced whole blood clot firmness. MedDRA version: 20.0 Level: PT Classification code 10037138 Term: Pseudomyxoma peritonei System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]
- United Kingdom
- 2018-06-29
Authorised
- Long term subcutaneous tinzaparin compared with tinzaparin and oral anticoagulants in the treatment of acute pulmonary embolism. A multicentre, prospective, randomised, open, parallel group clinical trial.
- Patients with clinical suspicion of Pulmonar Thromboembolism confirmed according to the PIOPED criteria. MedDRA version: 4.0 Level: PT Classification code 10037377
- Spain
- 2005-12-01
Authorised
- Nalmefene Efficacy Study II: Randomised, double-blind, placebo-controlled, parallel-group, efficacy study of 20 mg nalmefene, as needed use, in patients with alcohol dependence
- Alcohol dependence MedDRA version: 9.1 Level: LLT Classification code 10001594 Term: Alcohol dependence syndrome
- Belgium, Czech Republic, France, Italy, Poland, Portugal, Spain
- 2008-10-21
Authorised
- Pharmacokinetics and Safety of Human Pasteurised C1-Inhibitor Concentrate (Berinert/CE1145) in Subjects with Congenital C1-INH Deficiency.
- Hereditary Angioedema (HAE) MedDRA version: 14.1 Level: LLT Classification code 10056912 Term: C1 esterase inhibitor deficiency System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Italy
- 2012-12-19
Authorised
- A Study to Assess the Long-term Safety of Rechon Insulin Human Soluble in Type 1 Diabetic Patients.
- Type 1 Diabetes MedDRA version: 20.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Germany, Poland
- 2017-06-29
Authorised
- A Phase II Study of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea (HECNU) in pancreatic cancer - Phase II trial with FFC33
- Pancreatic cancer
- Austria
- 2005-07-20
